|Articles|February 1, 2005
New target, intervention for treating melanoma
Boston — New research discoveries demonstrate that melanoma is highly dependent on cyclin-dependent kinase 2 (CDK2) for growth and proliferation. Inhibiting expression of the gene regulating CDK2 stops the cancer dead in its tracks.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Recludix Pharma’s REX-8756 for Type 2 Inflammatory Diseases Enters First Human Trials
2
Oruka Reports Positive Interim Phase 1 Data for ORKA-002, Advances ORKA-001
3
Alpha Tau Submits First PMA Module to FDA for Novel cSCC Treatment, Alpha DaRT
4
Next-Generation IL-4Rα Targeting and Potential Dermatologic Implications
5














